CD4 and psoriasis: In addition, TAVO101 showed a trend of slightly more efficacious than tezepelumab in inhibiting TSLP-driven proliferation of activated CD4+ T cells in an ex vivo study and in an in vivo study with imiquimod induced psoriasis mouse model.